Sandoz Group stock

SDZ · SIX · CHF

Compare Sandoz Group
CHF 83.00Change from previous close: −1.89%Absolute change: −CHF 1.60

Close · November 17, 2026

Price history

+52.66% over the period

1 year: from CHF 54.92 (November 17, 2025) to CHF 83.84 (November 17, 2026), +52.66%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026CHF 83.84
October 30, 2026CHF 82.38
September 30, 2026CHF 70.86
August 31, 2026CHF 67.92
July 31, 2026CHF 65.76
June 30, 2026CHF 73.12
May 29, 2026CHF 65.60
April 30, 2026CHF 62.54
March 31, 2026CHF 61.74
February 27, 2026CHF 68.02
January 30, 2026CHF 61.18
December 30, 2025CHF 57.84
November 28, 2025CHF 56.72
November 17, 2025CHF 54.92

At a glance

  • The company

    Develops, manufactures and markets generic drugs and biosimilars for multiple therapeutic areas worldwide

  • Latest results

    Quarter to June 30, 2026 · EPS $0.25

TickerLandia's take on Sandoz Group

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowCHF 52.54
52-wk highCHF 86.90

−4.49% from the 52-week high

Analysts · 16 analysts

Average targetCHF 81.53−1.77% vs. price

Buy 7 · Hold 7 · Sell 2 · Buy

TickerLandia Fingerprint: Sandoz Group

Compared with similar companies: very strong momentum and very low profitability.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Sandoz Group is pricier than similar companies

Sandoz Group's P/E (trailing 12 months): 72.3, +190% against the median of a group of 11 similar companies (25.0).

Compared with 11 similar companies

Sandoz Group's metrics compared with similar companies
MetricSandoz GroupPosition in the groupBand
P/E (trailing 12 months)72.3High
Forward P/E22.0High
Operating margin9.3%Low
ROE7.2%Low
Debt/equity0.69High

Grey band: the middle half of the group; tick: the median; dot: Sandoz Group. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$5.78B

Latest quarter · Q2 2026

Net income

$109M

Latest quarter · Q2 2026

Quarterly net margin

1.9%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
CHF 36.61B
P/E
72.3
EPS
CHF 1.17
Volume
884.65K
Daily trading
€99.78M
Dividend yield
0.96%
Last ex-dividend on April 13, 2026

How Sandoz Group is changing

All results
  • Revenue grew 2.9% a year on average over the last 5 years

  • Profits turn into cash: free cash flow equal to 136% of net income

  • Revenue has grown for 3 fiscal years in a row

Returns

Sandoz Group returns with dividends

CHF 1,000 invested in Sandoz Group 3 years ago, on November 17, 2023, would be worth CHF 3,433 today with dividends reinvested: +243.28% in total, +50.84% per year. On price alone it would be CHF 3,283 (+228.27%).

PeriodSandoz GroupSMICHF 1,000 becomes
1 month+9.48%+4.53%CHF 1,095
6 months+26.76%+13.61%CHF 1,268
Year to date+44.95%+13.20%CHF 1,450
1 year+54.51%+19.22%CHF 1,545
3 years+243.28%+39.88%CHF 3,433

Over the last 6 months it has done better than 42% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment

The chart in detail

Sandoz Group: technical analysis

Sandoz Group is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 4.5% below its all-time closing high (CHF 86.90, November 12, 2026).

Trend
Upward
RSI (14 sessions)
57
Between 30 and 70
vs 200-session average
+20.82%

Support and resistance

Price areas where Sandoz Group has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last priceCHF 83.00
  3. SupportCHF 75.37−9.19%3 touches, last on October 28, 2026
  4. SupportCHF 72.20−13.01%2 touches, last on September 8, 2026
  5. SupportCHF 68.67−17.27%2 touches, last on May 13, 2026

Volatility and risk

Over the last year it has moved roughly in line with the SMI.

Beta (1 year) vs SMI
1.05
Volatility (60 sessions, annualised)
27.8%
Largest fall in the last year
−17.62%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

The company

Sandoz Group and its competitors

Sold worldwide, the generic and biosimilar medicines of Sandoz Group AG are developed, manufactured and marketed by the company across a wide range of therapeutic areas, including oncology, cardiovascular and central nervous system disorders, immunology, diabetes and ophthalmology. Its therapeutic coverage also extends to hematology, nephrology, neurology and endocrinology. Its offering includes active pharmaceutical ingredients and finished dosage forms. A strategic collaboration with Shanghai Henlius Biotech aims to broaden patient access to biosimilar medicines.

Headquarters
Basel, Switzerland
Employees
20,000
Founded
1886
Chief executive
Richard Saynor
Sandoz Group and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Sandoz GroupSDZ$43.57B9.3%72.3+26.76%
HaleonHLN$40.15B23.5%19.3+2.82%
Galderma GroupGALD$51.94B19.1%64.5+19.47%
MerckMRK$71.52B17.0%33.9+28.46%
Swedish Orphan BiovitrumSOBI$16.27B30.9%25.0+7.21%
IpsenIPN$14.2B27.4%25.5−1.14%

Same industry or related industries, similar size. Compare Sandoz Group with its competitors · Full profile